Clinical and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus

Lupus

Volumn 15, Issue 12, 2006, Pages 892-898

  Vilá, Luis M ^a   Molina, M J ^a   Mayor, A M ^b   Peredo, R A ^a   Santaella, M L ^a   Vila S ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b Universidad Central del Caribe School of Medicine   (Puerto Rico)

Author keywords

Autoantibodies; Clinical manifestations; Clinical outcome; Disease damage; Puerto Ricans; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; DNA ANTIBODY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHI SQUARE TEST; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; FISHER EXACT TEST; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PUERTO RICO; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; COHORT STUDIES; DNA; FEMALE; HISPANIC AMERICANS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PUERTO RICO; RIBONUCLEOPROTEINS; RIBONUCLEOPROTEINS, SMALL NUCLEAR;

EID: 33846007733     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306069352     Document Type: Article

References (50)

1. Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus 2004; 13: 290-297.
2. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994; 330: 1871-1879.
3. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 2003; 42: 276-279.
4. Pisetsky DS. Anti-DNA and autoantibodies. Curr Opin Rheum 2000; 12: 364-368.
5. López-Longo FJ, Monteagudo I, Gonzalez CM, Grau R, Carrero L. Systemic lupus erythematosus: clinical expression and anti-Ro/SSA response in patients with and without lesions of subacute cutaneous lupus erythematosus. Lupus 1997; 6: 32-39.
6. Saurit V, Campana R, Ruiz Lascano A et al. Mucocutaneous lesions in patients with systemic lupus erythematosus. Medicina 2003; 63: 283-287.
7. Reichlin M. Serological correlations with nephritis in systemic lupus erythematosus. Clin Immunol 2005; 117: 12-14.
8. Düzgün N, Hoier-Madsen M, Wiik A, Tokgöz G. The frequency of autoantibodies in Turkish patients with lupus nephritis. Rheumatol Int 1997; 17: 1-4.
9. García CO, Molina JM, Gutiérrez-Urueña S et al. Autoantibody profile in African-American patients with lupus nephritis. Lupus 1996; 5: 602-605.
10. Mitjavila F, Pac V, Moga I et al. Clinicopathological correlations and prognostic factors in lupus nephritis. Clin Exp Rheumatol 1997; 15: 625-631.
11. Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342-2349.
12. Sulcebe G, Morcka K. Diagnostic and prognostic significance of different antinuclear antibodies in more than 1000 consecutive Albanian patients with rheumatic diseases. Clin Exp Rheumatol 1992; 10: 255-261.
13. Zandman-Goddard G, Gilburd B, Shovman O et al. The homogeneous multiplexed system - a new method for autoantibody profile in systemic lupus erythematosus. Clin Dev Immunol 2005; 12: 107-111.
14. Molina JM, Molina J, García C, Gharavi AE, Wilson WA, Espinosa LR. Ethnic differences in the clinical expression of systemic lupus erythematosus: A comparative study between African-American and Latin Americans. Lupus 1997; 6: 63-67.
15. Vilá LM, Alarcón GS, McGwin G Jr et al. for the LUMINA Study Group. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) 2004; 43: 358-363.
16. Houman MH, Smiti-Khanfir M, Ben Ghorbell I, Miled M. Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients. Lupus 2004; 13: 204-211.
17. Vilá LM, Mayor AM, Valentín AH, García-Soberal M, Vilá S. Clinical and immunological manifestations in 134 Puerto Rican patients with systemic lupus erythematosus. Lupus 1999; 8: 279-286.
18. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
19. Cervera R, Kamashta MA, Font J et al. Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1,000 patients. Medicine 1993; 72: 113-124.
20. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Association of the Systemic Lupus Erythematosus International Collaborating Clinics/American College of Rheumatology Damage Index with systemic lupus erythematosus. J Rheumatol 1997; 24: 309-313.
21. Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T and the LJP 394 Investigator Consortium. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1129-1137.
22. Alba P, Bento L, Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62: 556-560.
23. Witte T, Hartung K, Matthias T et al. Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. SLE Study Group. Rheumatol Int 1998; 18: 63-69.
24. Colburn KK, Green LM, Wong AK. Circulation antibodies to guanosine in systemic lupus erythematosus: correlation with nephritis and polyserositis by acute and longitudinal analysis. Lupus 2001; 10: 410-417.
25. Chien JW, Lin CY, Yang LY. Correlation between anti-Ro/La titers and clinical findings of patients with systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 2001; 64: 283-291.
26. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology 2003; 42: 230-234.
27. Homma M, Mimori T, Takeda Y et al. Autoantibodies to the Sm antigen immunological approach to clinical aspects of systemic lupus erythematosus. J Rheumatol 1987; 14: 188-193.
28. Gregorio GV, Davies ET, Mieli-Vergani G, Vergani D. Significance of extractable nuclear antigens in childhood autoimmune liver disease. Clin Exp Immunol 1995; 102: 308-313.
29. Pradhan VD, Badakere SS, Bichile LS, Dolas MP. Antibodies to Ro/SS-A and La/SS-B in systemic lupus erythematosus and other autoimmune disorders. J Assoc Physicians India 2002; 50: 762-765.
30. Fritzler MJ, Kinsella TD. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980; 69: 520-526.
31. Synkowski DR, Reichlin M, Provost TT. Serum autoantibodies in systemic lupus erythematosus and correlation with cutaneous features. J Rheumatol 1982; 9: 380-385.
32. Ioannides D, Golden BD, Buyon JP, Bystryn JC. Expression of SS-A/Ro and SS-B/La antigens in skin biopsy specimens of patients with photosensitivity forms of lupus erythematosus. Arch Dermatol 2000; 136: 340-346.
33. Sutej PG, Gear AJ, Morrison RC et al. Photosensitivity and anti-Ro (SS-A) antibodies in black patients with systemic lupus erythematosus (SLE). Br J Rheumatol 1989; 28: 321-324.
34. Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti-SSA (Ro) antibodies. J Rheumatol 1989; 16: 479-481.
35. Inoue T, Okamura M, Negoro N et al. Anti-Ro/SS-A antibody-positive interstitial pneumonitis in a non-lupus patient. Osaka City Med J 1994; 40: 117-120.
36. Hedgpeth MT, Boulware DW. Interstitial pneumonitis in antinuclear antibody-negative systemic lupus erythematosus: a new clinical manifestation and possible association with anti-Ro (SS-A) antibodies. Arthritis Rheum 1988; 31: 545-548.
37. Erbey F, Cuhaci A, Incecik F et al. Neonatal lupus erythematosus presenting with cholestatic hepatitis: a case report and review of the literature. Turk J Pediatr 2005; 47: 63-66.
38. Zuppa AA, Delogu AB, De Rosa G et al. Neonatal lupus: different clinical neonatal expression in siblings. Arch Pediatr 2004; 11: 936-939.
39. Besson-Leaud L, Fontan D, Billeaud C, Sandler B. Neonatal lupus erythematosus and neurologic involvement: an incident association? Arch Pediatr 2002; 9: 503-505.
40. Weston WL, Morelli JG, Lee LA. The clinical spectrum of anti-Ro-positive cutaneous neonatal lupus erythematosus. J Am Acad Dermatol 1999; 40: 675-681.
41. Devesa IJ, Ferrando Ginestar J, Bustamante Balen M et al. Autoimmune hepatitis and anti-Ro antibodies. Is there a link? Gastroenterol Hepatol 2003; 26: 475-479.
42. Zonana-Nacach A, Camargo-Coronel A, Yanez P et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration. Lupus 1998; 7: 119-123.
43. Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Ugalde J, Aguirre C. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 2004; 13: 900-905.
44. Soares M, Reis L, Papi JA, Cardoso CR. Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients. Lupus 2003; 12: 788-794.
45. Karassa FB, Ioannidis JP, Boki KA, Touloumi G, Argyropoulou MI, Strigaris KA. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 2000; 109: 628-634.
46. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology 2004; 43: 1555-1560.
47. Vilá LM, Alarcón GS, McGwin G Jr, Baethge BA, Reveille JD. HLA-class II alleles among two distinct U.S. Hispanic populations with systemic lupus erythematosus. Association with clinical and immunologic manifestations. Arthritis Rheum 2003; 48: S574 (abstract).
48. Hasan T, Nyberg F, Stephansson E et al. Photosensitivity in lupus erythematosus, UV photoprovocation results compared with history of photosensitivity and clinical findings. Br J Dermatol 1997; 136: 699-705.
49. Vilá LM, Mayor AM, Valentín AH, Rodríguez SI, Reyes ML, Acosta E, Vilá S. Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. P R Health Sci J 1999; 18: 89-94.
50. Alarcón GS, Mc Gwin G Jr, Bastian HM et al. Systemic lupus erythematosus in three groups. VII. Predictors of early mortality in the LUMINA cohort. LUMINA study group. Arthritis Rheum 2001; 45: 191-202.